Guidelines for the administration of biological therapy in patients with inflammatory bowel diseases – the amendment to the 2^nd editon

Czech version

Authors: M. Lukáš Za Pracovní Skupinu Ibd Čgs; M. Lukáš On The Behalf Of Ibd Working Group Cgs
Published in: Gastroent Hepatol 2013; 67(4): 303-305
Category: IBD: Guidelines

Sources

1. Bortlík M, Ďuricová D, Kohout P et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: 2. vydání. Gastroent Hepatol 2012; 66(1): 12–22.

2. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for the induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60(6): 780–787.

3. Peyrin-Biroulet L, Laclotte C, Roblin X et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007; 13(16): 2328–2332.

4. Afif W, Leighton JA, Hanauer SB et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15(9): 1302–1307.

5. Taxonera C, Estellés J, Fernández-Blanco I et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011; 33(3): 340–348.

6. Lequoy M, Seksik P, Bouhnik Y et al. Efficacy of adalimumab in refractory ulcerative colitis in clinical practice. J Crohns Colitis 2013; 7: S217.

7. Barreiro-de Acosta M, García-Bosch O, Gordillo J et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012; 24(7): 756–758.

8. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate to severe ulcerative colitis. Gastroenterology 2012; 142(2): 257–265.

9. Reinisch W, Sandborn WJ, Panaccione R et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013; 19(8): 1700–1709.

10. Sandborn WJ, Colombel JF, D´Haens G et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37(2): 204–213.

11. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn´s disease: a systematic review. Am J Gastroenterol 2011; 106(4): 674–684.

12. Lukáš M. Rozšíří golimumab spektrum anti-TNF léčiv pro idiopatické střevní záněty? Gastroent Hepatol 2012; 66(6): 465–469.

13. Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352(24): 2499–2507.